Welcome to our dedicated page for Shattuck Labs news (Ticker: STTK), a resource for investors and traders seeking the latest updates and insights on Shattuck Labs stock.
Shattuck Labs, Inc. develops monoclonal and bispecific DR3-blocking antibodies for inflammatory and immune-mediated diseases. The company’s news centers on SL-325, a Death Receptor 3 antibody targeting the DR3/TL1A pathway, with emphasis on clinical development in inflammatory bowel disease and related immune-mediated conditions.
Recurring updates also cover quarterly financial results, cash and capital-structure disclosures, investor conference participation, inducement equity awards, and governance matters tied to Shattuck’s Nasdaq-listed common stock.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotech firm, announced its participation in the 22nd Annual Needham Virtual Healthcare Conference from April 17-20, 2023. The fireside chat will be held on April 19, 2023, featuring CEO Taylor Schreiber and CFO Andrew Neill, from 2:15 to 2:55 p.m. ET. The discussion will be available via live webcast and archived for 90 days. Shattuck is focused on developing bi-functional fusion proteins for treating cancer and autoimmune diseases, leveraging its proprietary ARC® platform and the SL-172154 program, currently in multiple Phase 1 trials.
The press release from Shattuck Labs (NASDAQ: STTK) highlights preclinical findings from the GADLEN platform presented at the AACR Annual Meeting. The CD20-targeted GADLEN demonstrated a rapid and efficient ability to deplete over 99% of human B cells in humanized mouse models and non-human primates without significant toxic effects. This promising data suggests potential for treating antibody-mediated autoimmune diseases. The GADLEN compound was well-tolerated at doses up to 25 mg/kg, indicating a favorable safety profile compared to existing T cell engagers.
Shattuck Labs, Inc. (NASDAQ: STTK) announced participation in two key investor conferences in March 2023. The Cowen 43rd Annual Health Care Conference will feature Dr. Lini Pandite discussing innovative oncology approaches on March 6 at 9:10 a.m. ET. On March 13, Dr. Taylor Schreiber will present a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference at 2:00 p.m. ET. Both events will be live-streamed and later archived on the company's website. Shattuck Labs is focused on advancing bi-functional fusion proteins targeting cancer and autoimmune diseases, with several ongoing Phase 1 trials, including its lead program SL-172154.
Shattuck Labs reported significant progress in clinical trials and announced key management changes. The Phase 1B trial of SL-172154 with mirvetuximab soravtansine in platinum-resistant ovarian cancer has begun enrollment. Initial data from this trial and others involving SL-172154 is expected in mid to late 2023. However, the company discontinued the SL-279252 program after failing to meet efficacy thresholds in Phase 1 trials. Financially, Shattuck reported a net loss of $25.4 million for Q4 2022, compared to a net income of $7.8 million a year prior, with R&D expenses rising to $82.9 million for the year. The company forecasts its cash reserves will sustain operations into H2 2024.